美國緝毒局對GW製藥公司批出醫療大麻油的壟斷權
DEA Grants Pharmaceutical Company Monopoly on Medical CBD
But that is not the case. The DEA decision applies only to “FDA-approved” drugs, meaning they have just granted GW Pharmaceuticals a monopoly on plant-derived CBD (hemp-derived CBD is no longer restricted). The DEA said as much in a statement to NBC affiliate WTHR:
“What this does not do is legalize or change the status of CBD oil products,” DEA spokesperson Rusty Payne said. “As of right now, any other CBD product other than Epidiolex remains a Schedule I controlled substance, so it’s still illegal under federal law.”
https://www.activistpost.com/2018/10/dea-grants-pharmaceutical-company-monopoly-on-medical-cbd.html
沒有留言:
發佈留言